Oncotelic Therapeutics Selects IBN for Corporate Communications Strategy

Oncotelic Therapeutics has selected IBN to spearhead its corporate communications, marking a strategic move for the clinical-stage biopharmaceutical company as it advances its pipeline of RNA-based immunotherapies and targeted treatments for cancer and underserved diseases. The company is currently progressing its lead candidate OT-101 through a Phase 3 trial for pancreatic ductal adenocarcinoma, one of the most challenging oncology indications with limited treatment options. This partnership with IBN's specialized communications platform comes at a critical juncture as Oncotelic seeks to enhance visibility for its innovative approaches to difficult-to-treat cancers and rare pediatric conditions.

The significance of this corporate communications initiative extends beyond mere publicity, as effective stakeholder communication is essential for clinical-stage biotechnology companies navigating complex regulatory pathways and seeking investment for continued research and development. Oncotelic's multi-asset pipeline, supported by proprietary AI platform PDAOAI and its 45% stake in GMP Biotechnology Limited, represents a substantial portfolio requiring strategic messaging to various audiences including investors, medical professionals, and patient advocacy groups. The company's focus on high-unmet-need cancers positions its communications strategy as particularly important for raising awareness about novel therapeutic approaches.

Led by Chairman and CEO Dr. Vuong Trieu, co-inventor of Abraxane, Oncotelic brings substantial scientific credibility to its development programs, with Dr. Trieu having filed over 150 patent applications and holding 39 issued U.S. patents. This expertise foundation, combined with the joint venture capabilities through GMP Bio that can support regulatory filings for up to 20 drug candidates, creates a compelling narrative for corporate communications. The selection of IBN, which provides access to a vast network of wire solutions via https://ibn.fm/PTeNg and delivers enhanced press release distribution to 5,000+ outlets, demonstrates Oncotelic's commitment to maximizing the impact of its scientific and clinical advancements.

For the biotechnology investment community and healthcare stakeholders, this communications partnership signals Oncotelic's maturation as a clinical-stage company preparing for potential regulatory milestones and market entry. The company's focus on pediatric cancers and aggressive solid tumors addresses significant unmet medical needs, making effective communication about trial progress and development timelines crucial for patient communities and treatment providers. As Oncotelic continues to advance its pipeline, the strategic corporate communications approach facilitated by IBN will play a vital role in shaping understanding of the company's technology platform, clinical progress, and potential impact on cancer treatment paradigms.